阿西替尼治疗儿童、年轻人和成人肾细胞癌后的结果：叙述性回顾。
Outcome after treatment with axitinib in children, young adults, and adults with renal cell carcinoma: a narrative review.
发表日期：2024 Sep 24
作者：
Julia Sprokkerieft, Justine N van der Beek, Filippo Spreafico, Barbara Selle, Tanzina Chowdhury, Norbert Graf, Arnauld C Verschuur, Rana Dandis, Axel Bex, James I Geller, Godelieve A M Tytgat, Marry M van den Heuvel-Eibrink
来源：
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
摘要：
肾细胞癌（RCC）是儿童和年轻人中非常罕见的肾癌类型。当转移或复发时，没有可用的护理标准，结果仍然很差。酪氨酸激酶抑制剂阿西替尼被批准用于治疗成人肾细胞癌，但其对患有肾细胞癌的儿童和年轻人的影响仍不清楚。由于儿童和成人之间的组织学和生物学差异，很难将成人的治疗知识推断到儿科和青少年环境。本文总结了接受阿西替尼治疗的肾细胞癌患者的临床特征和结果，旨在深入了解该化合物在这一年轻患者群体中的临床疗效。版权所有 © 2024 作者。由 Elsevier B.V. 出版。保留所有权利。
Renal cell carcinoma (RCC) is a very rare type of renal cancer in children and young adults. When metastasized or recurrent, no standards of care are available, and outcome is still poor. The tyrosine kinase inhibitor axitinib is approved for treatment of RCC in adults, but its effects in children and young adults with RCC remains unclear. Due to the histological and biological differences between children and adults, it is difficult to extrapolate knowledge on treatments from the adult to the pediatric and young adult setting. This paper summarizes the clinical characteristics and outcomes of patients with RCC who were treated with axitinib, with the aim to gain insight in the clinical efficacy of this compound in this young patient group.Copyright © 2024 The Authors. Published by Elsevier B.V. All rights reserved.